Acquisition History / Valerio Therapeutics SA / eTheRNA Immunotherapies NV
Valerio Therapeutics SA Acquires eTheRNA Immunotherapies NV
Announced August 24, 2026 — $35.1M
What happened
Valerio Therapeutics signed definitive agreements to acquire 100% of eTheRNA Immunotherapies NV, a Belgian mRNA immunotherapy company with a facility in Niel, based on an enterprise value of EUR 30 million on a debt-free, cash-free basis, subject to customary purchase price adjustments and contingent earn-out payments.
- Acquirer
- Valerio Therapeutics SA
- Target
- eTheRNA Immunotherapies NV
- Announced
- August 24, 2026
- Price
- $35.1M
- Industry
- Biotechnology / mRNA immunotherapies
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Valerio Therapeutics SA acquire eTheRNA Immunotherapies NV?
Valerio Therapeutics SA acquired eTheRNA Immunotherapies NV on August 24, 2026. This was Valerio Therapeutics SA's 1st publicly tracked acquisition out of 1 we have on record.
How much did Valerio Therapeutics SA pay for eTheRNA Immunotherapies NV?
Valerio Therapeutics SA paid $35.1M for eTheRNA Immunotherapies NV.
What does eTheRNA Immunotherapies NV do?
Valerio Therapeutics signed definitive agreements to acquire 100% of eTheRNA Immunotherapies NV, a Belgian mRNA immunotherapy company with a facility in Niel, based on an enterprise value of EUR 30 million on a debt-free, cash-free basis, subject to customary purchase price adjustments and contingent earn-out payments.
What other Biotechnology / mRNA immunotherapies companies has Valerio Therapeutics SA acquired?
eTheRNA Immunotherapies NV is Valerio Therapeutics SA's only publicly tracked acquisition in Biotechnology / mRNA immunotherapies so far.